Paper21746950
In vitro activity against Staphylococcus aureus of a novel antimicrobial agent, PRF-119, a recombinant chimeric bacteriophage endolysin.
Idelevich EA and 8 others. Antimicrob Agents Chemother, 2011. Cited by 46 papers, by iCite.
Cite this record
ConductScience Library. In vitro activity against Staphylococcus aureus of a novel antimicrobial agent, PRF-119, a recombinant chimeric bacteriophage endolysin. Papers, record 21746950. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/21746950
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- In vitro activity against Staphylococcus aureus of a novel antimicrobial agent, PRF-119, a recombinant chimeric bacteriophage endolysin.
- PubMed
Topics5
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anti-Bacterial Agents | Major topic |
| Endopeptidases | Major topic |
| Recombinant Proteins | Major topic |
| Staphylococcus aureus | Major topic |
| Microbial Sensitivity Tests |
Source PubMed
References35
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 16547033 | Cross-linked peptidoglycan mediates lysostaphin binding to the cell wall envelope of Staphylococcus aureus. | J Bacteriol | 2006 | https://conductscience.org/library/papers/16547033 | PubMed |
| 2 | 17955443 | Efficient elimination of multidrug-resistant Staphylococcus aureus by cloned lysin derived from bacteriophage phi MR11. | J Infect Dis | 2007 | https://conductscience.org/library/papers/17955443 | PubMed |
| 3 | 20452280 | Bacteriophage endolysins: a novel anti-infective to control Gram-positive pathogens. | Int J Med Microbiol | 2010 | https://conductscience.org/library/papers/20452280 | PubMed |
| 4 | 17085695 | Lytic activity of recombinant bacteriophage phi11 and phi12 endolysins on whole cells and biofilms of Staphylococcus aureus. | Appl Environ Microbiol | 2007 | https://conductscience.org/library/papers/17085695 | PubMed |
| 5 | 16445719 | Community-acquired methicillin-resistant Staphylococcus aureus: current perspectives. | Clin Microbiol Infect | 2006 | https://conductscience.org/library/papers/16445719 | PubMed |
| 6 | 15808314 | Thermonuclease gene as a target for specific identification of Staphylococcus intermedius isolates: use of a PCR-DNA enzyme immunoassay. | Diagn Microbiol Infect Dis | 2005 | https://conductscience.org/library/papers/15808314 | PubMed |
| 7 | 11739958 | Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase. | Science | 2001 | https://conductscience.org/library/papers/11739958 | PubMed |
| 8 | 20729317 | Inhibition of the activity of both domains of lysostaphin through peptidoglycan modification by the lysostaphin immunity protein. | Appl Environ Microbiol | 2010 | https://conductscience.org/library/papers/20729317 | PubMed |
| 9 | 16310147 | The role of nasal carriage in Staphylococcus aureus infections. | Lancet Infect Dis | 2005 | https://conductscience.org/library/papers/16310147 | PubMed |
| 10 | 18607587 | Lysostaphin: an antistaphylococcal agent. | Appl Microbiol Biotechnol | 2008 | https://conductscience.org/library/papers/18607587 | PubMed |
| 11 | 1406491 | Bacteriophage lysis: mechanism and regulation. | Microbiol Rev | 1992 | https://conductscience.org/library/papers/1406491 | PubMed |
| 12 | 5675508 | Susceptibility of coagulase-negative staphylococci to lysostaphin and other antibiotics. | Appl Microbiol | 1968 | https://conductscience.org/library/papers/5675508 | PubMed |
| 13 | 18843708 | Mupirocin ointment for preventing Staphylococcus aureus infections in nasal carriers. | Cochrane Database Syst Rev | 2008 | https://conductscience.org/library/papers/18843708 | PubMed |
| 14 | 20182526 | A poke into the diversity and associations within human anterior nare microbial communities. | ISME J | 2010 | https://conductscience.org/library/papers/20182526 | PubMed |
| 15 | 6639273 | Chemical composition and structure of cell wall teichoic acids of staphylococci. | Arch Microbiol | 1983 | https://conductscience.org/library/papers/6639273 | PubMed |
| 16 | 17997135 | Staphylococcus aureus of phage type 187 isolated from people occurred to be a genes carrier of eneterotoxin C and toxic shock syndrome toxin-1 (TSST-1). | Int J Hyg Environ Health | 2008 | https://conductscience.org/library/papers/17997135 | PubMed |
| 17 | 19673644 | Mupirocin resistance. | Clin Infect Dis | 2009 | https://conductscience.org/library/papers/19673644 | PubMed |
| 18 | 20661301 | Bacteriophage-resistant Staphylococcus aureus mutant confers broad immunity against staphylococcal infection in mice. | PLoS One | 2010 | https://conductscience.org/library/papers/20661301 | PubMed |
| 19 | 19913683 | Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008. | Diagn Microbiol Infect Dis | 2009 | https://conductscience.org/library/papers/19913683 | PubMed |
| 20 | 19451132 | Nasal decolonization of Staphylococcus aureus with mupirocin: strengths, weaknesses and future prospects. | J Antimicrob Chemother | 2009 | https://conductscience.org/library/papers/19451132 | PubMed |
Cited by36
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 46 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41601319 | Engineering a Potent Anti-MRSA Agent: The Development and Characterization of Chimeric Endolysin ZAM-MSC. | Iran Biomed J | 2025 | https://conductscience.org/library/papers/41601319 | PubMed |
| 41514460 | Clinical implementation of endolysins targeting gram-positive bacteria points toward a combination strategy with standard-of-care antibiotics: a selective review. | Eur J Med Res | 2026 | https://conductscience.org/library/papers/41514460 | PubMed |
| 41463785 | Recent Advances in Endolysin Engineering. | Antibiotics (Basel) | 2025 | https://conductscience.org/library/papers/41463785 | PubMed |
| 40328935 | [Phage endolysins-a novel class of antibacterial agents with a wide range of applications]. | Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz | 2025 | https://conductscience.org/library/papers/40328935 | PubMed |
| 39549153 | Phage-Derived Endolysins Against Resistant Staphylococcus spp.: A Review of Features, Antibacterial Activities, and Recent Applications. | Infect Dis Ther | 2025 | https://conductscience.org/library/papers/39549153 | PubMed |
| 39508962 | The Synergistic and Chimeric Mechanism of Bacteriophage Endolysins: Opportunities for Application in Biotherapeutics, Food, and Health Sectors. | Probiotics Antimicrob Proteins | 2025 | https://conductscience.org/library/papers/39508962 | PubMed |
| 37101261 | Therapeutic potential of bacteriophage endolysins for infections caused by Gram-positive bacteria. | J Biomed Sci | 2023 | https://conductscience.org/library/papers/37101261 | PubMed |
| 36112205 | Influence of NaCl and pH on lysostaphin catalytic activity, cell binding, and bacteriolytic activity. | Appl Microbiol Biotechnol | 2022 | https://conductscience.org/library/papers/36112205 | PubMed |
| 35208898 | Exploration of Bacterial Re-Growth as In Vitro Phenomenon Affecting Methods for Analysis of the Antimicrobial Activity of Chimeric Bacteriophage Endolysins. | Microorganisms | 2022 | https://conductscience.org/library/papers/35208898 | PubMed |
| 33519773 | Development of a Novel Chimeric Endolysin, Lys109 With Enhanced Lytic Activity Against Staphylococcus aureus. | Front Microbiol | 2020 | https://conductscience.org/library/papers/33519773 | PubMed |
| 32722499 | Characterization of Clinical MRSA Isolates from Northern Spain and Assessment of Their Susceptibility to Phage-Derived Antimicrobials. | Antibiotics (Basel) | 2020 | https://conductscience.org/library/papers/32722499 | PubMed |
| 32042832 | LytU-SH3b fusion protein as a novel and efficient enzybiotic against methicillin-resistant Staphylococcus aureus. | Mol Biol Res Commun | 2019 | https://conductscience.org/library/papers/32042832 | PubMed |
| 30889831 | Phage Endolysins as Potential Antimicrobials against Multidrug Resistant Vibrio alginolyticus and Vibrio parahaemolyticus: Current Status of Research and Challenges Ahead. | Microorganisms | 2019 | https://conductscience.org/library/papers/30889831 | PubMed |
| 30736446 | In Vitro Activity of the Bacteriophage Endolysin HY-133 against Staphylococcus aureus Small-Colony Variants and Their Corresponding Wild Types. | Int J Mol Sci | 2019 | https://conductscience.org/library/papers/30736446 | PubMed |
| 30459750 | Phage Lysins for Fighting Bacterial Respiratory Infections: A New Generation of Antimicrobials. | Front Immunol | 2018 | https://conductscience.org/library/papers/30459750 | PubMed |
| 29735560 | The Novel Phage-Derived Antimicrobial Agent HY-133 Is Active against Livestock-Associated Methicillin-Resistant Staphylococcus aureus. | Antimicrob Agents Chemother | 2018 | https://conductscience.org/library/papers/29735560 | PubMed |
| 29734776 | An Ointment Consisting of the Phage Lysin LysGH15 and Apigenin for Decolonization of Methicillin-Resistant Staphylococcus aureus from Skin Wounds. | Viruses | 2018 | https://conductscience.org/library/papers/29734776 | PubMed |
| 29596346 | 1st German Phage Symposium-Conference Report. | Viruses | 2018 | https://conductscience.org/library/papers/29596346 | PubMed |
| 29362234 | Are Phage Lytic Proteins the Secret Weapon To Kill Staphylococcus aureus? | mBio | 2018 | https://conductscience.org/library/papers/29362234 | PubMed |
| 29350135 | Plasmid-Encoded Transferable mecB-Mediated Methicillin Resistance in Staphylococcus aureus. | Emerg Infect Dis | 2018 | https://conductscience.org/library/papers/29350135 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/21746950
GET https://conductscience.org/api/papers/v1/21746950/references?page=2